Pentixapharm : Financial document (Presentation Earnings Call March 2026 PTX)

About this update from Pentixapharm Holding Ag

Fourth Quarter and FY 2025 Financial Results and Business Update Expanding the Boundaries of Radiopharmaceuticals March 26, 2026 Expanding the Boundaries of Radiopharmaceuticals Advanced clinical-stage Biotech Headquartered in Berlin, Germany More than 30 dedicated employees Pioneering Programs in Cardiovascular and Oncology Business Model R&D Model Expertise and resources Novel radiopharmaceuticals Strong clinical development expertise Solid global regulatory strategy High-quality CMC Strategic Backing Eckert & Ziegler backed platform with secured GMP supply infrastructure Focused clinical development through major value inflection points March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 3 Radiodiagnostics: High-resolution PET-CT imaging Imaging Stratify patients for tailored treatment Map disease distribution at baseline Track tumor burden with precision Radiotheranostics Seamlessly combining imaging and therapy to improve patient outcomes Radiotherapeutics: precision therapy Therapy Deliver targeted radioactive payload to tumor cells Destroys cancer cells through targeted radiation delivery Optimize tumor penetration / accessibility / lethality through choice of isotope Radiotheranostics: A New Paradigm in Precision Medicine March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 4 Focused Competencies at the Core of the Development Value chain Pentixapharm Core Expertise and Value Drivers Value Inflection In-license Discovery Pre-clinical IND/ CTIS Clinical Phase 1 Clinical Phase 2 Diagnostic Clinical Phase 3 Manufacturing Radionuclide Supply Research & Development combined with Regulatory strategy Outlicense CMC & radiopharmaceutical expertise Theranostic Clinical Phase 3 Approval & Commercialization March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 Inlicence & Outsource Development of proprietary assets Strategic Partnerships and Co-Development 5 Building Pipeline Momentum Across Oncology and Cardiology Lead Pre- IND/ Candidate Target Indication Optimization clinical CTIS Phase I Phase II Phase III Sponsor Radiodiagnostics PentixaFor PT-001 ⁶⁸Ga PANDA CXCR4 Cardiovascular Endocrine & Oncology Hypertension - Primary Aldosteronism Ph3 ready IITs Hypertension -Primary Aldorsteronism IIT Morbus Cushing PT-003 ¹⁸F CXCR4 (2 nd -Gen) Radiotheranostics CNS Lymphoma Ph1/2 IITs MM, NHL Myeloma IITs ALL/AML Solid Tumors (female cancers) CD24 GT-008 (IgG1 mAb Radioligand) TechnicalUniversity of Munich Centre Hospitalier Universitaire de Nantes emia and Multiple Leuk Hematologic cancers CXCR4 PentixaTher PT-002 90 Y, 177 Lu Multi Modal Antibody Pipeline CD44 Solid Tumors AML = Acute Myeloid Leukemia ALL = Acute Lymphoid Leukemia CNSL = Central Nervous System Lymphoma MM = Multiple Myeloma NHL = Non-Hodgkin Lymphoma RAC = Radioimmunoconjugates/Radiopharmaceutical Antibody Conjugates PT = Peptide based portfolio GT = Glyco-Antibody based portfolio March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 6 A Sharper, More Focused Pentixapharm Following Completed Streamlining Q1 Q2 Q3 Q4 Myelo001 Program discontinued following portfolio prioritization CXCR4 and CD24 Strategic re-orientation of non-clinical and clinical development Focus on clinical development in high-value Indications: Cardiovascular PANDA & Hem-Onc PENTHERA September 2025 PENTILULA Study Progress: PentixaTher AML Phase 1/2 study advanced to higher dose cohort October 2025 Data at EANM Conference: Extensive clinical data for PentixaFor presented December 2025 FDA Type B pre-IND: Feedback supports Phase 3 PANDA program March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 7 Pentixapharm FY 2025 Financials & Financial Guidance March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 8 Balance Sheet FY 2025 31.12.2025 31.12.2025 in € thousands 31.12.2024 in € thousands 31.12.2024 Assets Liabilities and Equity Subscribed capital 24.795 24.795 Capital reserves 37.475 38.727 Retained earnings/Accumulated deficit -11.927 -28.438 Treasury shares -12 -12 Equity attributable to shareholders of the parent company 50.331 35.072 Total equity 50.331 35.072 Non-current liabilities Deferred tax liabilities 3.930 3.328 Non-current provisions 2 0 Total non-current liabilities 3.932 3.328 Current liabilities Trade payables 8.943 2.435 Other current liabilities 5.098 1.024 Total current liabilities 14.041 3.459 Total liabilities and equity 68.304 41.859 Non-current assets Equity Other intangible assets 35.354 32.282 Property, plant and equipment 269 36 Deferred tax assets* 916 3.328 Financial assets 484 227 Total non-current assets 37.023 35.873 Current assets Cash and cash equivalents 23.232 4.624 Trade receivables 6.805 31 Income tax receivables 134 189 Other current assets 1.110 1.142 Total current assets 31.281 5.986 Total assets 68.304 41.859 *prior-year figure for deferred tax assets has been restated 9 Profit & Loss FY 2025 in € thousands 01-012/2024 01-12/2025 Revenue 118 93 Income from the sale of rights/patents 6.700 0 Other operating income 8.480 543 Cost of materials and external services for research and development -3.718 -6.796 Personnel expenses -1.431 -6.516 Other operating expenses -8.077 -3.454 Earnings before interest, taxes, depreciation, and amortization (EBITDA) 2.072 -16.130 Depreciation and amortization of non-current assets Earnings before interest and taxes (EBIT) -19.044 -16.972 -3.730 -19.860 Financial result 422 347 Earnings before taxes (EBT) -16.550 -19.513 Tax result* 4.623 3.002 Profit or loss/ Consolidated comprehensive income attributable to the shareholders of the parent company Earnings per share -11.927 -16.511 Diluted/ Basic (€ per share) 0 -1 Weighted average number of shares outstanding (diluted/ basic) - in thousands. 24.783 24.783 *prior-year figure for deferred tax assets has been restated 10 Cash Flow Statement FY 2025 in € thousands 01-12/2024 01-12/2025 Profit/loss -11.927 -16.511 Depreciation, amortization and impairment losses 19.044 3.730 Loss on disposal of fixed assets 0 200 Change in deferred taxes* -4.631 -3.015 Income taxes paid -36 -55 Other non-cash expenses/income -59 1.212 Change in trade receivables and other assets not attributable to investing or financing activities -7.583 7.053 Change in trade payables and other liabilities not attributable to investing or financing activities 864 -10.587 Cash flow from operating activities -4.328 -17.973 Payments for investments in intangible assets and property, plant and equipment -1 -625 Cash inflow from the contribution of Pentixapharm AG 8.707 0 Payments for acquisition of subsidiaries -470 0 Cash flow from investing activities: 8.236 -625 Proceeds from capital contributions 19.274 0 Cash flow from financing activities: 19.274 0 Effect of exchange rate changes on cash and cash equivalents 0 -10 Net increase/decrease in cash and cash equivalents 23.182 -18.608 Cash and cash equivalents at the beginning of the period 50 23.232 Cash and cash equivalents at the end of the period 23.232 4.624 *prior-year figure for deferred tax assets has been restated 11 FY 2026 Financial Guidance The Company guidance for the full year 2026 is as follows: FY 2026 Total Loss: €21,6 million R&D Expenses: €9,7 million Personnel & Other OPEX: €7,4 million Depreciation & Other non-cash expenses: €4,1 million Interest expenses: €0,4 million 12 Diagnostic and Therapeutic Program Overview March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 13 Targeting CXCR4: A Biologically Validated Target From Oncology to Cardiology - CXCR4 Anchors Next-Generation Radiopharmaceuticals CXCR4 : One of the most thoroughly researched biological targets of the last decade with a central role in the bone marrow CXCR4 Theranostic in Oncology: Key role in tumor growth and metastasis Highly present in multiple aggressive blood cancers Clinically validated in ~100 patients selected with ⁶⁸Ga-PentixaFor and treated with ⁹⁰Y- and 177 Lu-PentixaTher CXCR4 Diagnostics in Hypertension: Increased presence in adrenal tumors overproducing aldosterone Diagnostic marker to determine lateralization of aldosterone overproduction Emerging clinical evidence in ~1,600 patients diagnosed with ⁶⁸Ga-PentixaFor March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 14 Cardiovascular Program March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 15 The Problem: A Massively Underdiagnosed Disease 1.3B People with hypertension globally 5-10% Of hypertensives have Primary Aldosteronism ~2% Screening rate in resistant hypertension The Diagnostic Bottleneck More than > ~20% prevalence of Primary Aldosteronism in treatment-resistant HTN, yet only ~2% screened AVS (gold standard) is invasive, technically difficult, 30-96% success rates Result: Millions with potentially curable disease never reach surgery March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 AVS Bottleneck Patients with PA 16 Transforming the Diagnostic Pathway in Primary Aldosteronism Subtyping Subtyping Results Therapy Adrenal CT/ Adrenal Venous Sampling (AVS) Standard of Care Nonlateralizing PA (mostly BAH) 65% of the cases Mineralpocorticoid receptor antagonist (Lifelong medication) New Class of Aldosterone Synthase Inhibitors launch expected in H2 2026 Lateralizing PA (mostly unilateral) 35% of the cases Unilateral Adrenalectomy (Surgery) Patient with hypertension March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 17 Transforming the Diagnostic Pathway in Primary Aldosteronism Subtyping Subtyping Results Therapy [⁶⁸Ga]GaPentixaFor PET/CT Nonlateralizing PA (mostly BAH) 65% of the cases Mineralpocorticoid receptor antagonist (Lifelong medication) New Class of Aldosterone Synthase Inhibitors launch expected in H2 2026 Patient with hypertension Adrenal CT/ Adrenal Venous Sampling (AVS) Lateralizing PA (mostly unilateral) 35% of the cases Unilateral Adrenalectomy (Surgery) March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 18 P3 The New Hypertension Drug Class Aldosterone Synthase Inhibitor Wave: Billions Flowing Into Aldosterone-Driven HTN and Primary Aldosteronism The Market Opportunity ▼ Every ASI Rx triggers PA subtyping need ASI Peak Sales: $5B+ (baxdrostat alone) AstraZeneca paid $1.3B to acquire; projects major growth driver. Lorundrostat adds further expansion. Treatment-Resistant HTN: ~$10 to 15B by 2032 Fastest-growing segment (17% CAGR) Anti-HTN Drug Market: ~$27B (2025) 1.3 billion patients globally Cardiovascular & Endocrine Nea prec r-empty: non-o linical through ncology Phase 2 [ 68Ga]PentixaFor Neuro & CNS Primary aldosteron IND H1 2026 | FPI H2 ism 2026 Amyloid PET Tau PET Oncology Pluvicto Lutathera Xofigo PSMA PET Pylarifz /Illuccix Preclinical Phase 1 Phase 2 Phase 3 Approved Clincal stage Therapeutic (oncology) Therapeutic (non-oncology) Diagnostic (oncology) Diagnostic (non-oncology) PentixaFor Source: Frontiers in Medicine, Clinical Trials.gov, Citline Trialtrove, company disclosures. Bubble positions illustrative March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 19 Oncology Program March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 20 Where the Need Is Greatest: Global Incidence of Blood Cancers Requiring Bone Marrow Conditioning Global Incidence cases per year Central Nervous System Lymphoma ~10,000-12,000 Bone Marrow Conditioning & Treatment Acute Myeloid Leukemia ~145,000 Multiple Myeloma ~185,000 March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 21 Pentilula IIT Phase 1/2 Study of PentixaTher in Relapsed/Refractory Acute Myeloid Leukemia reached highest dose group ! Phase I/II study assessing radioligand therapy with [ 177 Lu]Lu-PentixaTher (PT-002) for relapsed/refractory CXCR4 + acute leukemia Primary Objective: To determine the MTD/DLT of Lu177-PentixaTher (PT-002) Population: n = 15 to 21 Relapsed or refractory CXCR4 + acute leukemia Methodology: 3+3 Design Imaging: 68 Ga-PentixaFor (PT-001) Therapy: Stand-alone [ 177 Lu]Lu-PentixaTher Sites: Clinic in France Timeline: Enrollment: 24m, Follow-up: 12m FPFV: Q424 LPLV: Q426 Data readout: Q427 CT Number: NCT06356922 Completed IIT: Investigator initiated study; ALL: Acute Lymphocytic Leukemia; AML: Acute Myeloid Leukemia; DLT: dose limiting toxicities March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 Cohort 1 2.5 GBq n = 3 / 2.5 mCi x 4 Secondary endpoints: Overall Rate of Response Complete Response Rate Overall Survival Leukemia-Free survival Primary endpoint: Number of participants with treatment-related adverse events Recommended Phase 2 Dose In Progress Cohort 4 10 GBq n = 3 / 2.5 mCi x 4 Cohort 5 12.5 GBq n = 3-6 / 2.5 mCi x 4 Escalation phase n ≈ 6-21 Expansion phase Cohort 2 5 GBq n = 3 / 2.5 mCi x 4 Completed Cohort 3 7.5 GBq n = 3 / 2.5 mCi x 4 Completed Completed 22 Targeting CD24: Highly Specific Cancer Therapy From Checkpoint Modulation to Targeted Radiotherapy -CD24 Antibody-Based Radioconjugates CD24: A growing body of translational and early clinical work positions CD24 as a new therapeutic gateway in oncology and immunology Targeting CD24 for payload delivery: Pentixapharm Solution: GT-008 monoclonal antibody targets a tumor-associated glycoform of CD24 Tum Tu o m r v o o r lu v m ol e u [ m m e m 3 ] Combines CD24 targeting with recognition of tumor-specific carbohydrate patterns, achieving superior tumor selectivity and enabling highly precise payload delivery Promising preclinical radioconjugate and antibody drug conjugate efficacy data for aggressive female cancers + 225 Ac-labeled GT-008 1500 Treatment 1000 500 Vehicle 225 Ac-GT-008 10 kBq 225 Ac-GT-008 3 kBq 0 7/8 CR 0 10 20 30 40 50 60 70 80 Days after randomization Complete response 7 out of 8 animals March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 23 2026 Outlook: Milestones March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 24 Upcoming Clinical Milestones Poised to Drive Significant Value Oncology Theranostic PTT101 & Investigator Initiated Studies (IIT) Oncology Diagnostic IIT Cardiovascular Primary Aldosteronism Phase III PANDA PROGRAM H1 2026 H2 2026 2027 2028 PANDA Phase 3 IND IND expt. H1 2026 Potential Fast-Track status c: PTT Hem-On Open IND H1 2026 PANDA Phase 3 Study FPFV expt. H2 2026 PANDA Phase 3 Study First 50 patients dosed in U.S./EU expt. H1 2027 IIT MM Diagnostic : Topline results expt. H2 2027 IIT AML Therapy: Topline results expt. H1 2027 PANDA Phase 3 Study Topline data expt. H2 2028 18F-CXCR4 P0/1 Study Results Ph0 expt. H2 2028 Start PhI/II expt. H2 2028 IIT MM Theranostic: Results expt. H2 2028 IIT AMLTheranostic: Results expt. H2 2028 Programs in italics contingent on future funding Cash Reach expected until March 2027 PTF = PentixaFor (radiodiagnostic) PTT = PentixaTher (radiotherapeutic) March 26, 2026 AML = Acute Myeloid Leukemia MM = Multiple Myeloma IND = Investigational New Drug Pentixapharm ・ Fourth Quarter and FY 2025 25 Transforming Personalized Medicine: Investment Highlights lue as Clinical-Stage Company Flagship Pipeline mpact of radiopharmaceuticals with Drives Near- and Long-Ter eline addressing high value biology PentixaFor/Ther: Phase 3-ready di cology and beyond hypertension with and precise ima in blood cancers, alongside first-in antibody platform g New e Indications ew indications and new targets : olutions for high unmet need in nd oncology Leveraging Strategic Supply Advantag gh-Growth Secured isotope access through Ec pportunities ensuring reliable scaling of diagnos aceutical market valued at 6.7-7.5 bn in therapeutic programs projected to be $14-16bn by 2033 Driving Va Advanced Broadening i advanced pip targets in on Pioneerin High-Valu Combining n generating s cardiology a m Impact agnostic in ging agent -class CD24 Seizing Hi Market O Radiopharm 2024-2025 e kert&Ziegler tic and March 26, 2026 Pentixapharm ・ Fourth Quarter and FY 2025 26 Thank you https://www.pentixapharm.com Attention : This is an excerpt of the original content. To continue reading it, access the original document here .

View stock analysis, news, and events for Pentixapharm Holding Ag